Skip to Main Content

Author Details

Laurence Collette
Belgium International Drug Development Institute
1995
222
84
PMIDPaper TitleJournal TitlePublished Year
37541279Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.Lancet Oncol2023
37711670Prechemotherapy Not Preorchiectomy Serum Tumor Markers Accurately Identify International Germ Cell Cancer Collaborative Group Prognostic Groups in Nonseminoma.Eur Urol Open Sci2023
37777577Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.Br J Cancer2023
34706141Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.BJU Int2022
35379637Diagnostic and prognostic factors in patients with prostate cancer: a systematic review.BMJ Open2022
35436524Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands cancer registry.J Clin Epidemiol2022
36199019The case against censoring of progression-free survival in cancer clinical trials - A pandemic shutdown as an illustration.BMC Med Res Methodol2022
32939818A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons.Biom J2021
33574142Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol.BMJ Open2021
33822655Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.J Clin Oncol2021
33872641Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis.Radiother Oncol2021
33729863Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.J Clin Oncol2021
33615533Correcting the bias of the net benefit estimator due to right-censored observations.Biom J2021
34771449Comparison of <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer.Cancers (Basel)2021
34310202Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease.J Clin Oncol2021
34333446The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.Eur J Cancer2021
33999161Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer: A Secondary Analysis of 2 Randomized Clinical Trials.JAMA Netw Open2021
33409773Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study.Eur Radiol2021
31331234Sample size computation in phase II designs combining the A'Hern design and the Sargent and Goldberg design.J Biopharm Stat2020
31908301Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.Lancet Oncol2020
31844960MRI versus <sup>18</sup>F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance.Eur Radiol2020
32055745Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studies.Contemp Clin Trials Commun2020
31718822Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.Eur Urol2020
32007209International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.Lancet Oncol2020
32337562Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials.Nephrol Dial Transplant2020
32552276Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.J Clin Oncol2020
32533240Impact of the COVID-19 crisis on imaging in oncological trials.Eur J Nucl Med Mol Imaging2020
29741569Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.Ann Oncol2019
31574418Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).Eur J Cancer2019
31227307Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).Eur Urol2019
31360890A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses.JNCI Cancer Spectr2019
30712798Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective.Lancet Oncol2019
30838405Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.J Natl Cancer Inst2019
30942180ESMO-MCBS: setting the record straight - Authors' reply.Lancet Oncol2019
30655100A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.Eur J Cancer2019
30395275Responding to the challenges of international collaborations between the east and the west - report of the first JCOG-EORTC symposium and a perspective from young JCOG and EORTC investigators.Jpn J Clin Oncol2019
30543350Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.JAMA Oncol2019
30419088Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial.JAMA Oncol2019
30326032Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.JAMA Oncol2019
29158104Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies.J Urol2018
30191850Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.Lancet Oncol2018
29960684Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042).Radiother Oncol2018
30141714Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials.Clin Trials2018
30624128FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.Scand J Urol2018
30303127Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.Lancet Oncol2018
29666994Whole body MRI in spondyloarthritis (SpA): Preliminary results suggest that DWI outperforms STIR for lesion detection.Eur Radiol2018
27607734Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial.JAMA Oncol2017
28173055Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership.Jpn J Clin Oncol2017
28490338International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer.Health Qual Life Outcomes2017
28961826Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001.Ann Oncol2017
  • 1 - 50 of 222

Recommended Authors

Rachel M Glicksman
University of Toronto, Princess Margaret Cancer Centre, University Health Network
Career Start Year 2013
Number of shared co-authors 14
William C Jackson
University of Michigan ann arbor
Career Start Year 2013
Number of shared co-authors 18
Nicholas G Zaorsky
University Hospitals Seidman Cancer Centre, Cleveland Medical Centre
Career Start Year 2012
Number of shared co-authors 25
Alan Dal Pra
University of Miami Miller School of Medicine
Career Start Year 2010
Number of shared co-authors 15
Jure Murgic
University Hospital Center Sestre Milosrdnice
Career Start Year 2008
Number of shared co-authors 8
Bridget F Koontz
Duke University School of Medicine
Career Start Year 2006
Number of shared co-authors 14
Rahul D Tendulkar
Taussig Cancer Institute, Cleveland Clinic
Career Start Year 2006
Number of shared co-authors 15
Nicholas van As
The Institute of Cancer Research, Royal Marsden NHS Foundation Trust
Career Start Year 2005
Number of shared co-authors 6
Ananya Choudhury
University of Manchester and The Christie NHS Foundation Trust
Career Start Year 2004
Number of shared co-authors 14
Alejandro Berlin
University of Toronto, Princess Margaret Cancer Centre
Career Start Year 2004
Number of shared co-authors 29
Gregory R Pond
Juravinski Hospital and Cancer Centre, Escarpment Cancer Research Institute
Career Start Year 2001
Number of shared co-authors 12
Chandana A Reddy
Cleveland Clinic
Career Start Year 2000
Number of shared co-authors 18
Robert B Den
Thomas Jefferson University Hospital
Career Start Year 1999
Number of shared co-authors 18
Mark K Buyyounouski
Stanford University
Career Start Year 1999
Number of shared co-authors 17
Wolfgang Lilleby
Oslo University Hospital
Career Start Year 1999
Number of shared co-authors 17
Danny Vesprini
University of Toronto, Canada Odette Cancer Centre
Career Start Year 1998
Number of shared co-authors 9
Gert De Meerleer
University Hospitals Leuven
Career Start Year 1997
Number of shared co-authors 17
Inge M van Oort
Radboud University Medical Center
Career Start Year 1995
Number of shared co-authors 20
Almudena Zapatero
University Hospital La Princesa
Career Start Year 1995
Number of shared co-authors 27
Xavier Maldonado
Hospital Universitari Vall d'Hebron
Career Start Year 1994
Number of shared co-authors 19
Jonathan D Tward
Huntsman Cancer Institute, University of Utah
Career Start Year 1994
Number of shared co-authors 15
William Robert Lee
Duke University School of Medicine
Career Start Year 1993
Number of shared co-authors 18
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 11
Thomas M Pisansky
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 26
Richard Choo
Mayo Clinic
Career Start Year 1991
Number of shared co-authors 13
David Joseph
Sir Charles Gairdner Hospital
Career Start Year 1990
Number of shared co-authors 22
Peter Hoskin
Mount Vernon Cancer Centre
Career Start Year 1985
Number of shared co-authors 19
Maha Hussain
Northwestern University
Career Start Year 1984
Number of shared co-authors 19
Mack Roach
University of California San Francisco
Career Start Year 1983
Number of shared co-authors 34
Howard I Scher
Memorial Sloan Kettering Cancer Center
Career Start Year 1973
Number of shared co-authors 20

Collaborators

Michel Bolla
universite Grenoble-Alpes (UGA)
Co-authored papers 33
Theo M de Reijke
Amsterdam University Medical Centers, University of Amsterdam
Co-authored papers 19
Ronald de Wit
Erasmus MC Cancer Institute
Co-authored papers 17
Philippe Maingon
Pitie-Salpetriere Hospital, AP-HP.Sorbonne Universite
Co-authored papers 17
Cora N Sternberg
Meyer Cancer Center, Englander Institute for Precision Medicine
Co-authored papers 14
Hendrik Van Poppel
University Hospitals Leuven
Co-authored papers 11
Cornelis J H van de Velde
Leiden University Medical Center: Leids Universitair Medisch Centrum.
Co-authored papers 5
Theodorus H van der Kwast
University Health Network, University of Toronto
Co-authored papers 5
Jeff A Sloan
Mayo Clinic
Co-authored papers 4
Melanie Calvert
Institute of Applied Health Research, University of Birmingham
Co-authored papers 4
Howard M Sandler
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 4
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 3
Bengt Glimelius
Uppsala University
Co-authored papers 3
Anthony V D'Amico
Duke University Medical Center
Co-authored papers 3
Philippe Lambin
Maastricht University
Co-authored papers 3
Eric Winquist
Schulich School of Medicine and Dentistry, University of Western Ontario
Co-authored papers 3
Meredith M Regan
Co-authored papers 3
Robert E Reiter
David Geffen School of Medicine at university of california los angeles
Co-authored papers 2
Nicholas G Nickols
University of California, Veteran Affairs Greater Los Angeles Healthcare System
Co-authored papers 2
Alexandra Drakaki
David Geffen School of Medicine at university of california los angeles
Co-authored papers 2
Patrick A Kupelian
university of california los angeles Medical Center
Co-authored papers 2
Michael L Steinberg
University of California los angeles
Co-authored papers 2
Kiri A Sandler
Oregon Health and Science University
Co-authored papers 2
Amar U Kishan
University of California los angeles
Co-authored papers 2
Vincenzo Valentini
Universita Cattolica del Sacro Cuore
Co-authored papers 2
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Co-authored papers 2
Joost J C Verhoeff
University Medical Center Utrecht
Co-authored papers 2
Matthew B Rettig
David Geffen School of Medicine, University of California los angeles
Co-authored papers 2
Sandra J Strauss
University College London, Cancer Institute
Co-authored papers 2
Mieke Van Hemelrijck
School of Cancer and Pharmaceutical Sciences, King's College London
Co-authored papers 2
Release 1.2